2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 343-345
Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Immunotherapy, Biological Processes, Hematopoiesis, Immune Mechanism, Diseases, Immunology, GVHD, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Animal Model
PAPER

698 Thymus-derived regulatory NK cells restrict graft-versus-host disease without compromising anti-tumor immunity

Madeline Patricia Lauener, PhD, Anastasia I. Kousa, PhD2, Ashley Huang3, Alima Suleimenova4, Naomi Lee, DVM5, Jennifer Angelica Funes, MS6, Nathan Duong, BS7, Miriam Martinez8, Nastaran Abbasizadeh9, Daniel Ghazarian10, Preet Kaur, PhD11, Kirk Schultz, MD12, Andri Leo Leo Lemarquis, MD,PhD13, Marcel R.M. van den Brink Jr, M.D., Ph.D.14
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 BC Children's Hospital & BC Women's Hospital Health Plus Health Centre, Vancouver, British Columbia, Canada
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 BC Children's Hospital & BC Women's Hospital Health Plus Health Centre, Vancouver, British Columbia, Canada
13 Karolinska Institute, Solna, Sweden
14 City of Hope National Medical Center, Duarte, California, United States

Suppression of alloreactive T cells remains a major limitation of current therapies for graft-versus-host disease (GVHD), as broad immune inhibition can compromise graft-versus-tumor (GVT) activity and protective immunity. The presence of NK cells has been associated with improved outcomes after allogeneic hematopoietic cell transplantation (allo-HCT). However, whether these cells have therapeutic properties remains undefined.

To characterize regulatory pathways within innate lymphocytes, we generated a single-cell atlas of murine innate lymphoid and NK cells across nine target tissues of allo-HCT. NK cells segregated into classical cytotoxic, mature and ILC1-like NK cells. In addition, we identified a distinct population expressing high Cd27, low Cd11b, and lack of cytotoxic genes. These cells were enriched for known regulatory genes such as the inhibitory ligand PD-L1. Spectral flow confirmed presence of CD27⁺CD11b⁻PD-L1⁺ cells. To test their function, we performed in vitro coculture assays indicating suppression of CD4⁺ T cell proliferation and inflammatory cytokine production (IFNγ, TNFα) without suppressing CD8⁺ T cells. Suppression was non-cytolytic, required contact, and was abrogated by PD-1 antibody blockade and genetic PD-L1 deletion. We thus defined these cells as regulatory NK cells (NKregs).

Mapping of NKregs across tissues indicated highest frequency in the thymus, where regulatory gene expression was also highest. To test whether NKregs are derived from thymic lymphoid progenitors we used RAG1 fate mapping, which showed preferential RAG1 history in NKregs versus cytotoxic NK cells. To test dependency, we used both RAG1 deficient and athymic NKregs. In both models, NKregs lost suppressive phenotype and function while gaining cytotoxicity. Meanwhile, thymus transplantation in athymic hosts restored NKreg phenotype and function. Phenotyping of lymphoid derived transcription factors identified high expression of TCF7 in NKreg cells. In addition, CUT&RUN of TCF7 in NKregs revealed distinct occupancy of TCF7 at regulatory loci with strong binding at the promoter of PD-L1, identifying TCF7 as a potential regulator of NKreg suppression.

Using an MHC-disparate allo-HCT model (C57BL/6J to BALB/cJ), we investigated the presence and function of NKregs before and after transplant. During GVHD, NKregs were preferentially lost compared with cytolytic NK cells, with the most pronounced reduction in the thymus. To determine their functional role, NK cells were depleted using anti-NK1.1 or anti-asialo-GM1 antibodies. NK depletion significantly worsened GVHD, resulting in increased IFNγ production, enhanced donor T-cell infiltration, and reduced survival. We next evaluated NKreg adoptive transfer as a therapeutic strategy. NKreg treatment improved survival and reduced systemic inflammation, including IFNγ levels. Transfer of NKregs also reduced donor CD4+ T-cell accumulation in blood and target tissues and lowered tissue injury. Mechanistically, PD-L1-deficient NKregs failed to confer protection, demonstrating that NKreg-mediated suppression of GVHD requires PD-L1.

Because preservation of GVT activity is critical after allo-HCT, we tested whether NKregs impair antitumor immunity. NKregs did not inhibit CD8+ T-cell-mediated killing of A20 lymphoma cells in vitro and maintained tumor killing. In vivo, NKreg transfer reduced GVHD while preserving tumor control, supporting separation of GVHD from GVT effects.

In humans, we identified a putatively analogous population of CD56brightCD16⁻ NK cells. These cells expressed TCF7 and PD-L1, exhibited low granzyme B and perforin expression, and selectively suppressed allo-CD4⁺ T-cell proliferation. Human thymic organoids generated CD56brightCD16⁻ NKreg cells with a similar phenotype. Organoid-derived NKregs also preserved CD4⁺ T-cell suppressive function. To determine whether human NKregs retain therapeutic activity in vivo, expanded NKregs were evaluated in a xenogeneic GVHD model in NSG mice receiving human PBMCs. Human NKreg treatment significantly reduced GVHD severity and improved survival compared with controls.

In summary, we identify both in mice and humans a thymus-derived TCF7hiPD-L1⁺ NKreg population that selectively suppresses CD4⁺ T cells through a PD-L1–dependent mechanism. NKregs are lost in GVHD but can be restored to reduce inflammation, protect tissue integrity, improve survival, and preserve GVT, defining a conserved innate regulatory axis with therapeutic potential.

 

Madeline Patricia Lauener, PhD: No relevant conflicts of interest to declare.